Risperidone Augmentation for Treatment-Resistant Aggression in ADHD
Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
Primary objectives:
1. To assess the short-term efficacy of risperidone augmentation for treatment-resistant
aggression in children with ADHD.
2. To assess the short-term safety and tolerability of risperidone augmentation in the same
group of subjects.